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Vectors derived from human immunodeficiency virus-1 (HIV-1) are highly efficient vehicles for gene 
delivery. The present study aimed to establish a potent expression system of human factor VIII (FVIII) 
with lentiviral vectors. FVIII≥BD gene was obtained by enzyme digestion and inserted into lentiviral 
vector pXZ208 driven by cytomegalovirus (CMV) promoter/enhancer. Recombinant viral particles were 
prepared by cotransfection of 293T cells with packaging plasmids ≥NRF and VSV-G through calcium 
phosphate precipitation. A variety of cell lines including 293T, HLF, NIH3T3, BMEC, Chang-Liver cells 
and MSCs were infected with recombinant virus containing FVIII≥BD. The expression of FVIII≥BD 
mRNA, FVIII procoagulant activity and genomic DNA integration were detected. All the above cell lines 
were successfully transfected by recombinant lentiviruses. The transfection efficiencies in 293T, HLF, 
NIH3T3, BMEC, Chang-Liver cells and MSCs were 59.57 ± 5.24, 74.52 ± 7.57, 41.33 ± 5.82, 42.34 ± 5.84, 
14.38 ± 2.73% and 27.24 ± 6.53, respectively. All the cell lines expressed FVIII after infection to different 
extents and the activity of FVIII in 293T, HLF, NIH3T3, mBMEC, Chang-Liver cells and MSCs was 43.2 ± 
3.2, 54.1 ± 5.6, 14.2 ± 2.8, 8.7 ± 1.3, 22.5 ± 2.9 and 12.5 ± 2.7%, respectively. In addition, FVIII≥BD mRNA 
and genomic DNA integration were detected in all cell lines after transfection. A novel lentiviral vector 
carrying human FVIII≥BD was constructed, which was able to transfect different mammalian cell types 
accompanied by high-level activity. This lentiviral vector may provide a theoretical basis for the gene 
therapy of patients with hemophilia A.  
 





Hemophilia A is an x-linked recessive bleeding disease 
which is characterized by deficiency of blood coagulation 
factor VIII (FVIII) and frequent hemarthrosis, leading to 
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prophylactically (Hilgartner, 2002). Purified FVIII 
concentrates concentrated from human peripheral blood 
or produced by recombinant DNA and genetic engineering 
technology are now available for replacement therapy 
and clinical effectiveness has been achieved (White et 
al., 1988). However, the replacement therapy has been 
demonstrated to have some complications. The common 
and severe adverse effects include: (a) Production of 
antibodies against exogenous FVIII; (b) contamination by 
hepatitis B and C; (c) risk of HIV infection (Jones, 1991; 
Ragni, 1998; Hoyer, 1995; Eyster et al., 1992).  
Recent advances in molecular biology and genetic 
engineering have made gene replacement therapy possible 
for patients with hemophilia A. Although major progres-
sion has been achieved in the replacement therapy of 
hemophilia A using various gene delivery systems, critical 
limitations remain the major concerns (Roth et al., 2001; 





2005) and more attention has been paid to the in vivo 
gene transfer methods (Kaiser, 2004). Evidence indicated 
that retroviral vectors were able to integrate into promoter 
and regulatory elements of human genome, increasing 
the possibilities of insertional oncogenesis in gene 
therapy (De Palma et al., 2005; Hacein-Bey-Abina et al., 
2003). 
 Lentiviral vectors derived from human immuno-
deficiency virus-1 (HIV-1) have attracted attention of 
numerous investigators due to their ability to transfect 
non-dividing cells and low immunogenicity. The present 
study aimed to investigate the transduction efficiency of 
HIV-1-based lentiviral vector, and detect the expression 
of target gene in a variety of cell lines transfected with 
lenviral vector in vitro.  
 
 
MATERIALS AND METHODS 
 
Construction of the lentiviral expression vector 
 
Both self-inactivating (SIN) lentiviral vectors pXZ171 and pXZ208 
driven by CMV promoter were used in this study. pXZ171 carrying 
target gene, the enhanced green fluorescent protein (GFP) served 
as the control, of which the vector was previously constructed by 
our laboratory (unpublished data). An Xholfragment containing 
human B-domain-deleted coagulation factor FVIII (FVIII≥BD) gene 
was excised from pDLZ6, which was kindly provided by Dr. Hengjun 
Chao (University of North Carolina at Chapel Hill, USA) (Chao et 
al., 2000), and inserted into the XholI site of pXZ208 to construct 
lentiviral expression vector pXZ208-FVIII≥BD. The sequence 
orientation was verified by XholI and KpnI restriction digestion 
analysis. The packaging plasmid pMD.G, encoding vesicular stomotitis 
virus G (VSV-G) envelope protein and the plasmid pCMV≥8.91 
expressing HIV structure gene have been previously described 
(Zufferey et al., 1997). 
 
 
Cell lines  
 
Chang-liver cells (kindly provided by Dr. Li Xuexia, Xuzhou Medical 
College), brain microvascular endothelia cells (BMEC) (Dr. Ding 
Daofang, Shanghai Jiaotong University School of Medicine), 293T 
and NIH3T3 cells (brought from ATCC) were maintained in 
Dulbecco’s modified Eagle medium in humidified air with 5% CO2. 
HLF cells were grown in modified RPMI 1640 medium (Gibco) 
supplemented with 10% fetal calf serum (FCS) in humidified air 
containing 5% CO2. Human bone marrow mesenchymal stem cells 
(MSCs) were isolated and purified as previously described 
(Krampera et al., 2003; Van Damme et al., 2006). 
 
 
Preparation of lentiviral vectors 
 
Viral particles were generated by cotransfection of 293T cells with 
packaging mix as previously described with minor modifications 
(Naldini et al., 1996; Chen and Okayama, 1987). 293T cells were 
seeded in 10-cm plates at a density of 2×105 cells/ml 24 h prior to 
transfection. The medium was changed with that free of serum and 
antibiotics 3 h before transfection. A total of 30 g of vectors, 
including 10 g of pXZ208-FVIII≥BD, 15 g of pCMV8.91 and 5 
g of pMD.G, were suspended in a solution containing 125 l of 1 M 
CaCl2, 375 l of steriled water, and 500 l of 2× borate buffered 
saline, which was incubated at room temperature for 20 min, 
followed by transferring into the plates. FCS  was  supplemented  at  




the final concentration of 10%. The medium containing lentiviral 
particles was collected 48 h after transfection, sterilized through 




Determination of viral titers  
 
To determine viral titers, 293T cells were seeded at 2 × 105 cells per 
well in 6-well plates and maintained for 6 h. The supernatant was 
replaced with 1 ml of diluted or undiluted vector supernatant 
containing pXZ171-GFP, followed by incubation overnight. Then, the 
supernatant was replaced with fresh medium. 48h after lentiviral 
infection, the cells were observed under fluorescent microscope 
and the percentage of GFP positive cells was counted. Titers were 
calculated using the following formula:  
 
Titers (infection unit/ml, IU/ml) = GFP positive cells × dilution 
multiple (Li et al., 2004).  
 
 
Cell transfection  
 
Cells were seeded at a density of 1 × 105/well. 24 h later, the 
medium was removed and replaced with 5 ml of medium containing 
8 g/ml polybrene and viral vectors. 48 h later, the GFP-positive 
cells were counted under fluorescent microscope and analyzed by 
flow cytometry (FCM). 
 
 
Assay of coagulation factor activity  
 
The supernatant of infected cells was collected for FVIII activity 
assay with one-stage method (Factor Deficient Plasmas, Pacific 
Hemostasis, USA) 48 h after transfection. 
 
 
Detection of FVIII≥BD mRNA expression  
 
Total RNA extracted from cultured cells were used for reverse 
transcription (RT)-PCR (RNAgents® Total RNA Isolation System  
Access RT-PCR System, Promega). The primers and reaction 
conditions were described elsewhere (Chao et al., 2000). Briefly, 
the forward primer 5’-TTCTCCCCAATCCAGCTGG-3’, and the 
reverse primer 5’-GAGTTATTTCCCGTTGATGG -3’ were used to 
amplify a 534 bp fragment. Reverse transcription contained 
denaturation at 42°C for 10 min and termination reaction at 95°C for 
5min. The cycling conditions for PCR were 30 cycles of denaturation 
(95°C for 2 min), annealing (55°C for 1 min) and extension (72°C 
for 1 min). A preheating step at 95°C for 5 min and a final extension 
step consisting of 4 min at 72°C were also carried out.  
 
 
Detection of DNA integration of FVIII≥BD  
 
To verify whether the FVIII≥BD was stably integrated into the 
genomic DNA, high molecular weight DNA was isolated using the 
Wizard® Genomic DNA Purification Kit (Promega) according to the 
manufacturer’s instructions. PCR-based amplification of the target 
fragment was performed and the cycling conditions were prede-
naturation at 94°C for 5 min, followed by 30 cycles of 94°C for 2 





Data are presented as mean ± SD. The means of transduction 
efficiencies   and  FVIII  secretion  levels  of  cells  transduced  were  




   
Figure 1. Restriction enzyme map of 
recombinant plasmid pXZ208-BDDh FVIII. 
M: 1,000 bp DNA Ladder; 1: pXZ208-
FVIII≥BD (Xhol I); 2: pXZ208- FVIII≥BD 





compared with the use of a 2-tailed paired student’s t test. Statistical 





Verification of transfer vector  
 
The recombinant FVIII≥BD fragment was inserted into the 
downstream of CMV promoter to construct the 
recombinant vector pXZ208-FVIII≥BD. The full length of 
pXZ208-FVIII≥BD was 13,018 bp. After digestion with 
XholI, two fragments, 4435 and 8583 bp were obtained 
(Figure 1, lane 1). Digestion with KpnI resulted in 
fragments of 3341 and 9677 bp (Figure 1, lane 2). pXZ 
208 was also excised with XholI or KpnI as blank vector 
control (Figure 1, lanes 3 and 4).  
 
 
Detection of transfection efficiency of the recombinant 
vector GFP expression by fluorescent microscopy  
 
The viral titers were as high as 2.18 ± 0.64 × 106 IU/ml, 
which could be further concentrated to 109 IU/ml. Cells 
were exposed to pXZ171-GFP at a concentration of 106 
IU/ml for 48 h. The expression of GFP varied among 
different cell lines. GFP was highly expressed in 293T 
and HLF cells, whereas the green fluorescent signals 
were relatively weak in BMEC cells (Figure 2). The 
number of GFP positive cells in 293T and HLF cells was 





2). These findings were further confirmed by FCM analysis 
(Table 1). The transfection efficiencies of different cell 
types were compared and the results showed that the 
transfection efficiency was highest (P < 0.05) in HLF 
cells, while the lowest transfection efficiency was noted in 
BMECs (P < 0.05) (Figure 3).  
 
 
Detection of FVIII≥BD mRNA and protein activity in 
different cell types  
 
293T, HLF, NIH3T3, BMEC, Chang-Liver cells and MSCs 
were transfected with lentiviral vectors. The results 
showed that therapeutic factor VIII activity levels were 
observed in all cell types transfected with lentiviral 
vectors (Table 2). RT-PCR was performed to verify the 
mRNA expression of FVIII≥BD. The results demonstrated 
that the fragment of target gene (534 bp) was amplified in 
all cell lines (Figure 4).  
 
 
DNA integration of FVIII≥BD  
 
Primers were designed for the detection of specific FVIII≥ 
BD gene fragment. A specific fragment of 534 bp 
spanning the genomic integration site and FVIII≥BD 
fragment were amplified in all cell types with lentiviral 
vector transfection. No target fragment was observed in 





HIV-based lentiviral vectors are highly efficient gene 
delivery vehicles. However, one major concern in clinical 
trials is its biosafety. In earlier reports, viral particles were 
generated to simultaneously express viral core enzymes 
and other capsid proteins. This method gives rise to 
replication competent lentiviruses (RCLs). To make the 
HIV-based vectors safer, a major modification of HIV-
based lentiviral vector was made in the present study. 
Promoter and enhancer elements of the U3 region of long 
terminal repeat (LTR) were removed in our vector series. 
The 3’ LTR-directed transcription was eliminated in these 
vectors resulting in SIN of these vectors following 
transfection. The use of VSV-G as virus envelope confers 
stability to the particle and facilitates particle concentration 
during collection (Burns et al., 1993). Viral particles are 
traditionally produced by transient cotransfection of 293T 
packaging cells with three or four different plasmids 
encoding pol II core enzymes and capsid proteins. The 
absence of overlapping sequences between plasmids 
minimizes the possibility of generation of RCL (Aiken, 
1997; Parolin et al., 1994). Up to date, no RCLs have 
been generated from SIN vectors when they were used 
as gene delivery vehicles in vivo (Naldini et al., 1996; 
Zufferey et al., 1997; Miyoshi et al., 1997; Goldman et al., 
1997; Levine et a., 2006). Furthermore, because  no  viral  






Figure  2.  GFP expression in target cells 48 h after transfection (×100). A, B, C, D, E and F were 
representative fluorescent photographs of 293T, HLF, NIH3T3, BMEC, Chang-liver cells and MSCs, respectively, 




Table 1. Transfection efficiency 48 h after infection. 
 
Cell type n Transfection efficiency (%) 
293T 7 59.57±5.24 
HLF 5 74.52±7.57 
NIH3T3 4 41.33±5.82 
MSCs 4 42.34±5.84 
Chang-liver  5 27.24±6.53 
BMECs 6 14.38±2.73 
 
P < 0.05 vs. 293T, MSCs, BMECs, Chang-liver cells and 
NIH3T3; P < 0.05 vs. NIH3T3, 293T, MSCs, HLF and 




proteins are expressed, these vector systems will not 
trigger an immune response against cells expressing vector 
proteins in vivo.  
In the present study, virus titers were as high as 2.18 ± 
0.64 × 106 IU/ml. Similar to previous studies, we have 
used human HIV-1-based lentiviral vectors for stable 
gene transfer because it was found that these vectors 
could efficiently transduce a variety of nondividing cells in 
vivo (Naldini et al., 1996; Naldini et al., 1996; Miyoshi et 
al., 1997; Kafri et al., 1997). Although relatively high 
transfection efficiency was observed in all cell lines, the 
transduction efficiency varied profoundly in different cell 
types. The transductions resulted in different levels of 
FVIII secretion. FVIII:C levels corresponded to different 
virus titers per 48 h and were among the highest levels 
reported for FVIII so far in other recombinant systems. 
Therapeutic levels of FVIII secretion in 293T and HLF 
transduced with the same vector but 10- to 20-fold lower 
levels in MSCs and BMECs that were transduced with 
the same transgene cassette could also be achieved. 
More GPF-positive cells in 293T and HLF were observed 
compared to those in NIH3T3, BMECs, Chang-Liver cells 
and MSCs. This may be attributed to, at least in part, the 
activation status and cell cycle phases. In addition, cell 
surface receptor for virus may also be responsible for 
various transfection efficiencies (Grant and David, 2004). 
Transfection efficiency in MSCs was up to 5% which has 
been reported in the detection using electroporation 
(Matthews et  al.,  1993).The  present  studies  suggested  










Table 2. Activity of FVIII in different cell types 48 h after transfection. 
 
Cell type n APTT (s) FVIII activity (%) 
293T 7 68.5 ± 4.1 43.2 ± 3.2 
HLF 6 63.1 ± 6.1 54.1 ± 5.6 
NIH3T3 6 93.1 ± 5.7 14.2 ± 2.8 
MSCs 6 97.4 ± 7.4 12.5 ± 2.7 
Chang-liver cells  6 81.5 ± 6.3 22.5 ± 2.9 
BMECs 6 102.6 ± 4.8 8.7 ± 1.3 
 
P < 0.05 vs. 293T, MSCs, BMECs, Chang-liver cells and NIH3T3; P 
<0.05 vs. NIH3T3, 293T, MSCs, HLF and Chang-Liver cells; APTT, 






Figure 4. Expression of FVIII≥BD mRNA detected by RT-PCR. A. Lane 1, 3, 5 were 293T, NIH3T3, 
and HLF cells, respectively; Lane 2, 4, 6 were controls; B. Lane 1, 3, 5 were MSCs, BMECs and 




that higher transduction efficiency could be achieved in 
MSCs, resulting in higher FVIII activity in vitro. Ideal gene 
therapy aimed to integrate the target gene into the host 
genome with long-term expression. In the  present  study,  






Figure 5. DNA integration of FVIII≥BD detected by PCR. A. Lane 1, 3, 5 were 293T, NIH3T3, and HLF cells, respectively; 





PCR confirmed gene integration in all cell lines with 





The present study provided a basis for further investi-
gating HIV-1-based lentiviral vectors in gene therapy of 
patients with hemophilia A ex vivo. But it raised several 
issues. Constant efforts should be made toward the 
standardization in isolation and purification of MSCs. 
Some investigators have demonstrated that viral injury 
causes normally quiescent cells to progress into the cell 
cycle to enhance lentiviral transduction. For this reason, 
to produce therapeutic levels of coagulation factors, 
techniques need to be developed to promote cell cycle 
progression in a safer, nonsurgical manner, such as the 
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